Summary
Definition
History and exam
Key diagnostic factors
- presença de fatores de risco
- preocupação excessiva que dura há, pelo menos, 6 meses
- ansiedade não limitada a outro transtorno mental
- ansiedade não decorrente de medicamento ou substância
- tensão muscular
- perturbação do sono
- fadiga
- sono agitado
- irritabilidade
- baixa concentração
Other diagnostic factors
- cefaleia
- sudorese
- tontura
- sintomas gastrointestinais
- dores musculares
- frequência cardíaca aumentada
- dispneia
- tremores
- resposta de sobressalto exagerada
- dor torácica
Risk factors
- história familiar de ansiedade
- estresse emocional ou físico
- história de trauma emocional, físico ou sexual
- outro transtorno de ansiedade
- doença física crônica
- sexo feminino
Diagnostic investigations
1st investigations to order
- diagnóstico clínico
Investigations to consider
- testes da função tireoidiana
- exame de urina para detecção de drogas
- urina de 24 horas para catecolaminas, metanefrinas, normetanefrinas e creatinina
- testes de função pulmonar
- eletrocardiograma (ECG)
Treatment algorithm
sintomas de ansiedade que satisfazem os critérios do DSM-5-TR
sintomas de ansiedade que não preenchem os critérios do DSM-5-TR
Contributors
Authors
Philip John Cowen, MD, FRCPsych, FMedSci
Professor of Psychopharmacology
Department of Psychiatry
University of Oxford
Oxford
UK
Disclosures
PJC declares that he has no competing interests.
Acknowledgements
Professor Philip John Cowen would like to gratefully acknowledge Dr Christopher Gale, Dr Richard P. Swinson, Dr Elizabeth Hoge, and Dr Phebe Tucker, previous contributors to this topic.
Disclosures
CG is an author of the Royal Australian and New Zealand College of Psychiatrists clinical practice guideline on social phobia, panic disorder, and generalised anxiety disorder. Otago University has commercial and research relationships with multiple pharmaceutical companies. He is an author of a number of references cited in this topic. RPS has personally received royalties for articles published in UpToDate (Wolters Kluwer) and the Compendium of Therapeutic Choices, 2nd edition (Canadian Pharmacists Association). EH is an author of a number of references cited in this topic. PT has conducted research for GlaxoSmithKline, Bristol-Myers Squibb, Wyeth Pharmaceuticals, Astra-Zeneca, Cephalon, Inc., and Ortho-McNeil. She has also consulted for Forest Pharmaceuticals and received honoraria from Pfizer, Inc. and Forest Pharmaceuticals.
Peer reviewers
Lori Davis, MD
Research Director
University of Alabama
School of Medicine Tuscaloosa Campus
College of Community Health Sciences
Tuscaloosa
AL
Disclosures
LD declares that she has no competing interests.
Arianna Di Florio, MD, PhD
Senior Clinical Lecturer
Division of Psychological Medicine and Clinical Neurosciences
Cardiff University
United Kingdom
Disclosures
ADF declares that she has no competing interests.
Elaine Lockhart, MD, BCH, BAO
Consultant in Paediatric Liaison Psychiatry
Royal Hospital for Children
Glasgow
United Kingdom
Disclosures
EL declares that she has no competing interests.
Differentials
- Transtorno de pânico
- Transtorno da ansiedade social
- Transtorno obsessivo-compulsivo
More DifferentialsGuidelines
- Treatment and management of mental health conditions during pregnancy and postpartum
- Generalised anxiety disorder and panic disorder in adults: management
More GuidelinesPatient information
Anxiety: what is it?
Anxiety: questions to ask your doctor
More Patient informationLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer